hexamethylene bisacetamide has been researched along with Neoplasms in 16 studies
N,N'-diacetyl-1,6-diaminohexane: chemical name obtained from Acta Biol Hung 1990;41(1-3):199-208
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hexamethylene bisacetamide was administered as a 5% (w/v) solution via a nasogastric or gastrostomy tube every 4 h for 5 days, followed in 21 days by a 5-day continuous i." | 2.67 | Phase I bioavailability and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered via nasogastric tube. ( Chun, HG; Kelley, JA; Leyland-Jones, B; Lombardo, FA; Roth, JS; Ward, FT; Weiss, RB, 1991) |
| "Hexamethylene Bisacetamide (HMBA) is a hybrid polar compound originally developed as a differentiation inducing agent." | 1.35 | Hexamethylene bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NF kappaB activity: implications for cancer therapy. ( Dey, A; Kua, N; Lane, D; Teo, HL; Tergaonkar, V; Wong, E, 2008) |
| "Hexamethylene bisacetamide (HMBA) is a potent in vitro differentiating agent that has clinical potential as an anticancer drug both as a single agent and as a component of combination therapy." | 1.29 | Simultaneous measurement of the cell-differentiating agent hexamethylene bisacetamide and its metabolites by gas chromatography. ( Chun, HG; Kelley, JA; Roth, JS; Ward, FT, 1994) |
| "6 g/m2/day), we attempted to individualize each patient's dose based on a dosing scheme using an adaptive (feedback) control algorithm, which assumed linear clearance for HMBA." | 1.28 | Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580). ( Conley, BA; Egorin, MJ; Forrest, A; Sinibaldi, V; Van Echo, DA; Zuhowski, EG, 1989) |
| " In this dose-finding and pharmacokinetic study, five dosage levels were explored from 12 to 28 g/m2/day." | 1.27 | Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals. ( Baltzer, L; Declan Walsh, T; Fanucchi, MP; Gordon, C; Marks, PA; Rifkind, RA; Stevens, YW; Tong, W; Yaldaei, S; Young, CW, 1988) |
| " The fraction of dose excreted in urine as AcHA was not affected by HMBA dosage and accounted for 12." | 1.27 | Plasma pharmacokinetics and urinary excretion of hexamethylene bisacetamide metabolites. ( Callery, PS; Cohen, AS; Egorin, MJ; Geelhaar, LA; Van Echo, DA; Zuhowski, EG, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (37.50) | 18.7374 |
| 1990's | 8 (50.00) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dey, A | 1 |
| Wong, E | 1 |
| Kua, N | 1 |
| Teo, HL | 1 |
| Tergaonkar, V | 1 |
| Lane, D | 1 |
| Wang, QH | 1 |
| Xie, Y | 1 |
| Fan, HH | 1 |
| Gao, L | 1 |
| Liu, Y | 1 |
| Xie, YH | 1 |
| Roth, JS | 2 |
| Kelley, JA | 2 |
| Chun, HG | 3 |
| Ward, FT | 2 |
| Toren, A | 1 |
| Rechavi, G | 1 |
| Beere, HM | 1 |
| Hickman, JA | 1 |
| Conley, BA | 2 |
| Egorin, MJ | 4 |
| Sinibaldi, V | 2 |
| Sewack, G | 1 |
| Kloc, C | 1 |
| Roberts, L | 1 |
| Zuhowski, EG | 3 |
| Forrest, A | 3 |
| Van Echo, DA | 4 |
| Lombardo, FA | 1 |
| Weiss, RB | 1 |
| Leyland-Jones, B | 2 |
| Marks, PA | 5 |
| Rifkind, RA | 4 |
| Dmitrovsky, E | 1 |
| Markman, M | 1 |
| Young, CW | 1 |
| Fanucchi, MP | 1 |
| Declan Walsh, T | 1 |
| Baltzer, L | 1 |
| Yaldaei, S | 1 |
| Stevens, YW | 1 |
| Gordon, C | 1 |
| Tong, W | 1 |
| Sheffery, M | 1 |
| Ramsay, R | 1 |
| Ikeda, K | 1 |
| Hoth, D | 1 |
| Shoemaker, D | 1 |
| Wolpert-DeFilippes, M | 1 |
| Grieshaber, C | 1 |
| Cradock, J | 1 |
| Davignon, P | 1 |
| Moon, R | 1 |
| Rifkind, R | 1 |
| Cohen, AS | 1 |
| Geelhaar, LA | 1 |
| Callery, PS | 1 |
| Sigman, LM | 1 |
| Whitacre, MY | 1 |
| Aisner, J | 1 |
6 reviews available for hexamethylene bisacetamide and Neoplasms
| Article | Year |
|---|---|
Differentiation: a suitable strategy for cancer chemotherapy?
Topics: Acetamides; Animals; Antineoplastic Agents; Cell Differentiation; Drug Therapy, Combination; Gene Ex | 1993 |
Role of differentiation induction in tumor suppression.
Topics: Acetamides; Animals; Antineoplastic Agents; Cell Differentiation; Drug Evaluation; Drug Resistance; | 1990 |
Approaches to more effective induction of cytodifferentiation of transformed cells and potential for cancer treatment.
Topics: Acetamides; Animals; Cell Differentiation; Humans; Leukemia, Erythroblastic, Acute; Neoplasms; Oncog | 1990 |
Clinical use of differentiating agents in cancer therapy.
Topics: Acetamides; Animals; Antineoplastic Agents; Cell Differentiation; Cytarabine; Humans; Neoplasms; Ret | 1990 |
Induction of transformed cells to terminal differentiation.
Topics: Acetamides; Animals; Cell Differentiation; Cell Transformation, Neoplastic; Cell Transformation, Vir | 1987 |
Hexamethylene bisacetamide: a polar-planar compound entering clinical trials as a differentiating agent.
Topics: Acetamides; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Cell Line | 1986 |
1 trial available for hexamethylene bisacetamide and Neoplasms
| Article | Year |
|---|---|
Phase I bioavailability and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered via nasogastric tube.
Topics: Acetamides; Adult; Aged; Biological Availability; Confusion; Drug Evaluation; Female; Gastrointestin | 1991 |
9 other studies available for hexamethylene bisacetamide and Neoplasms
| Article | Year |
|---|---|
Hexamethylene bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NF kappaB activity: implications for cancer therapy.
Topics: Acetamides; Animals; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Surviv | 2008 |
[Effect of HMBA on differentiation and apoptosis of HL-60 and U937 cells and its mechanism].
Topics: Acetamides; Apoptosis; Cell Cycle Proteins; Cell Differentiation; Gene Expression; HL-60 Cells; Huma | 2004 |
Simultaneous measurement of the cell-differentiating agent hexamethylene bisacetamide and its metabolites by gas chromatography.
Topics: Acetamides; Aminocaproates; Aminocaproic Acid; Antineoplastic Agents; Chromatography, Gas; Diethyl P | 1994 |
What really cures in autologous bone marrow transplantation? A possible role for dimethylsulfoxide.
Topics: Acetamides; Bone Marrow; Bone Marrow Purging; Bone Marrow Transplantation; Cell Differentiation; Dim | 1993 |
Approaches to optimal dosing of hexamethylene bisacetamide.
Topics: Acetamides; Acidosis; Adult; Aged; Bicarbonates; Clinical Trials, Phase I as Topic; Dose-Response Re | 1992 |
Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580).
Topics: Acetamides; Algorithms; Antineoplastic Agents; Drug Evaluation; Humans; Neoplasms; Thrombocytopenia | 1989 |
Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals.
Topics: Acetamides; Adult; Aged; Antineoplastic Agents; Cell Line; Drug Evaluation; Female; Humans; Infusion | 1988 |
Plasma pharmacokinetics and urinary excretion of hexamethylene bisacetamide metabolites.
Topics: Acetamides; Antineoplastic Agents; Biotransformation; Dose-Response Relationship, Drug; Humans; Neop | 1987 |
Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
Topics: Acetamides; Acidosis; Drug Administration Schedule; Drug Evaluation; Hematopoiesis; Humans; Kidney; | 1987 |